Riskpilot← Back to searchSign inGet full accessFrimurer Holdings ApS
APSActiveCVR 39786494Under Elmene 11, 2. thActivities of holding companies · NACE 6421Est. 2018— employees
Revenue 2024
DKK -6K
0% vs 2023
EBITDA margin
100.0%
0% vs 2023
Equity ratio
-507.9%
Financial strength
Net profit 2024
DKK -7K
-1% vs 2023
| Revenue | DKK -6K | +0% |
| EBITDA | DKK -6K | +0% |
| Net profit | DKK -7K | -1% |
| Total assets | DKK 8K | — |
| Equity | DKK -41K | -22% |
| Employees | — | — |
Legal name
Frimurer Holdings ApS
CVR number
39786494
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
15. august 2018
Share capital
DKK 40.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af hele direktionen i forening eller af en direktør alene.
Company purpose
Selskabets formål er at foretage investeringer i aktiver, herunder immaterielle, og aktiviteter relaterede til forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler til diagnosticering, behandling og/eller forebyggelse af, primært, kræft og kræftrelaterede sygdomme, og andre hermed relaterede aktiviteter, samt at yde konsulentydelser til selskaber, som er beskæftigede indenfor selskabets hovedformål.
Address
Under Elmene 11, 2. th
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | -6 | -6 | -6 | -6 | -6 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -6 | -6 | -6 | -6 | -6 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -6 | -6 | -6 | -6 | -6 |
| Net financials | 927 | -927 | -1 | -1 | -1 |
| Profit before tax | 921 | -933 | -7 | -7 | -7 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | 921 | -933 | -7 | -7 | -7 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 927 | 0 | 0 | 0 | 8 |
| Equity | 915 | -19 | -26 | -33 | -41 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13 | 19 | 26 | 33 | 49 |
| Total debt | 13 | 19 | 26 | 33 | 49 |
EBITDA margin
-625000.0%
This company
15.8%
Market median
-3955796% vs market
20202024
Equity ratio
-507.9%
This company
38.2%
Market median
-1430% vs market
20202024
Return on equity
-729000.0%
This company
18.4%
Market median
-3962057% vs market
20202024
Net profit margin
-729000.0%
This company
8.1%
Market median
-9000100% vs market
20202024
Asset turnover
-0.78×
This company
1.12×
Market median
-170% vs market
20202024
Debt / equity
1.20×
This company
0.62×
Market median
-94% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
No data on file.
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Frimurer Holdings ApS 
Solid Therapeutics ApSBoard members of Frimurer Holdings ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|